tiprankstipranks
Trending News
More News >
Amarin Corporation Plc (AMRN)
:AMRN
US Market
Advertisement

Amarin (AMRN) Earnings Dates, Call Summary & Reports

Compare
3,253 Followers

Earnings Data

Report Date
Mar 03, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.03
Last Year’s EPS
-2.4
Same Quarter Last Year
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Oct 29, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook due to significant growth in U.S. market sales, successful partnerships, and strategic cost reductions. However, challenges remain with declining Rest of World revenue and ongoing restructuring costs.
Company Guidance
During Amarin Corporation's third-quarter 2025 earnings call, the company reported a total net revenue of $49.7 million, marking a 17% increase compared to the previous year. This growth was primarily driven by the U.S. net product revenue, which reached $40.9 million, a 34% increase due to changes in customer mix and regained exclusivity with a large pharmacy benefit manager. The company has successfully transitioned to a fully partnered commercial model outside the U.S., with the European operations handed over to Recordati, generating $4.1 million in product revenue. The company also reported significant operational cost savings, reducing SG&A expenses by 47% year-over-year, and anticipates achieving positive free cash flow by 2026. Despite a decline in rest-of-world revenue, the company remains focused on leveraging its partnerships to expand VASCEPA's market reach globally, with a strategic emphasis on cardiovascular risk reduction. The FDA's recent labeling update on fenofibrates is expected to further highlight VASCEPA's benefits.
Increase in Total Net Revenue
Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year period, primarily reflecting higher U.S. sales.
U.S. Market Performance
Net product revenue in the U.S. was $40.9 million, an increase of $10.3 million or 34%, driven by an increase in net selling price and volume.
Successful Partnership with Recordati
The transition to a fully partnered commercial model in Europe is progressing well, with sustained momentum and growth in demand across all commercialized European markets.
Cost Savings and Restructuring
SG&A expenses were reduced by $17.2 million or 47% over the prior year period, indicating the benefits of organizational restructuring.
FDA Labeling Update on Fenofibrates
The FDA revised the labeling of fenofibrates to include a statement on the lack of cardiovascular benefit, which may shift clinical practice towards proven therapies like VASCEPA.

Amarin (AMRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

AMRN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 03, 2026
2025 (Q4)
0.03 / -
-2.4
Oct 29, 2025
2025 (Q3)
-0.43 / -0.02
-1.298.33% (+1.18)
Jul 30, 2025
2025 (Q2)
-0.25 / -0.03
0
May 07, 2025
2025 (Q1)
-0.77 / -0.04
-0.490.00% (+0.36)
Mar 12, 2025
2024 (Q4)
-1.06 / -2.40
-0.2-1100.00% (-2.20)
Oct 30, 2024
2024 (Q3)
-1.11 / -1.20
-1-20.00% (-0.20)
Jul 31, 2024
2024 (Q2)
-0.85 / 0.00
-0.8
May 01, 2024
2024 (Q1)
-0.60 / -0.40
-0.850.00% (+0.40)
Feb 29, 2024
2023 (Q4)
-0.54 / -0.20
0
Nov 01, 2023
2023 (Q3)
-0.90 / -1.00
-0.2-400.00% (-0.80)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

AMRN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 29, 2025
$18.94$16.81-11.25%
Jul 30, 2025
$14.65$14.97+2.18%
May 07, 2025
$10.19$10.18-0.10%
Mar 12, 2025
$9.41$8.00-14.98%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amarin Corporation Plc (AMRN) report earnings?
Amarin Corporation Plc (AMRN) is schdueled to report earning on Mar 03, 2026, Before Open (Confirmed).
    What is Amarin Corporation Plc (AMRN) earnings time?
    Amarin Corporation Plc (AMRN) earnings time is at Mar 03, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is AMRN EPS forecast?
          AMRN EPS forecast for the fiscal quarter 2025 (Q4) is 0.03.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis